UniSA’s PhD students Chelsea Thorn and Hayley Schultz have just returned to work after an amazing business trip around the USA and Canada in July. The trip was funded by Hayley’s UniSA Research Degree Excellence Grant and the CBNS Student Travel Award and Chelsea’s Young Pharmacist Professional Innovation Grant.
Together, Chelsea and Hayley visited two research groups (Professor Hageman at Kansas University in Lawrence and Professor Howell at Sick Kids Research Institute in Toronto) and three pharmaceutical industry sites (Pfizer in Groton, and Bristol Myers-Squibb in New Brunswick and Princeton). They also attended the four-day Controlled Release Society conference in New York. Both had the opportunity to present their 30-minutete talks to the research groups and industries (a total of five talks) and a poster presentation at the conference. Hayley and Chelsea received lots of helpful advice and words of encouragement on their research projects and praise on their initiative to tour the USA and Canada.
Chelsea says, “The trip to North America was a fantastic opportunity to increase our research exposure and foster relationships with collaborators. For me, it was a pleasure to meet Professor Howell face to face and further plan my project with Sick Kids. The added bonus of interacting with the pharmaceutical industry has also given me a sound insight into potential career prospects”.
“We’ve come back to Australia with a greater understanding of how research is conducted in North America in both an academic and industry setting. We now realise that our skills are actually very applicable to industry and that it is a very possible career pathway for us to consider. It has been an eye opening experience and I hope to maintain the connections I’ve built with all the amazing researchers we’ve had the pleasure of meeting.”. Hayley states.
Chelsea is due to head overseas again in September to Scotland for the International Pharmaceutical Federation (FIP) meeting and will meet Hayley in Singapore in late September to attend the Globalised Pharmaceutics Education Network (GPEN) and Controlled Release Asia conferences.